| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.M300539200 |
| P698 | PubMed publication ID | 12893832 |
| P50 | author | Yong Song Gho | Q87855760 |
| Young-Yun Kong | Q89294464 | ||
| P2093 | author name string | Il-Jun Kang | |
| Young-Mi Kim | |||
| Soo-Young Lee | |||
| Young-Myeong Kim | |||
| Young-Guen Kwon | |||
| Jeong-Ki Min | |||
| Eok-Cheon Kim | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor | Q24328901 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 | ||
| TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 | ||
| Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras | Q28238120 | ||
| The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor | Q28285539 | ||
| Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells | Q28375565 | ||
| Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium | Q28512027 | ||
| High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis | Q28594191 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria | Q29616614 | ||
| Transformation of mammalian cells by constitutively active MAP kinase kinase | Q29618686 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells | Q31660362 | ||
| Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src | Q33871655 | ||
| Angiogenesis and bone growth | Q34204716 | ||
| TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts | Q38310846 | ||
| Osteolysis and cancer | Q39946675 | ||
| Regulation of osteoclastogenesis and RANK expression by TGF-beta1. | Q40778414 | ||
| Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts | Q40879592 | ||
| Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway | Q40919226 | ||
| Role of osteoblasts in hormonal control of bone resorption—A hypothesis | Q41551873 | ||
| Molecular mechanisms of blood vessel formation | Q41560712 | ||
| HMEC-1: establishment of an immortalized human microvascular endothelial cell line | Q41592068 | ||
| VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation | Q41672985 | ||
| Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption | Q41772601 | ||
| VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells | Q42815794 | ||
| An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression | Q43668422 | ||
| TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells | Q43821708 | ||
| Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. | Q46288581 | ||
| Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis | Q73684776 | ||
| Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines | Q74269794 | ||
| The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling | Q77206124 | ||
| Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells | Q77759136 | ||
| Cartilage to bone--angiogenesis leads the way | Q77890101 | ||
| Immunolocalisation of vascular endothelial growth factor (VEGF) in human neonatal growth plate cartilage | Q78121264 | ||
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| NF-κB | Q411114 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 39548-39557 | |
| P577 | publication date | 2003-07-31 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand | |
| P478 | volume | 278 |
| Q89818706 | A Network Pharmacology Approach to Estimate the Active Ingredients and Potential Targets of Cuscutae semen in the Treatment of Osteoporosis |
| Q54684809 | Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1. |
| Q35569854 | An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction |
| Q92636699 | Clinical Impact of RANK Signalling in Ovarian Cancer |
| Q50939159 | Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. |
| Q91003903 | Didymin by suppressing NF-κB activation prevents VEGF-induced angiogenesis in vitro and in vivo |
| Q37690180 | Double-antiangiogenic protein DAAP targeting vascular endothelial growth factor A and angiopoietins attenuates collagen-induced arthritis |
| Q35557415 | Effects of SU5416 and a vascular endothelial growth factor neutralizing antibody on wear debris-induced inflammatory osteolysis in a mouse model |
| Q39637435 | Effects of vascular endothelial growth factor (VEGF) on MC3T3-E1 |
| Q35133898 | Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran |
| Q36524247 | Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid |
| Q24299177 | Expression and function of RANK in human monocyte chemotaxis |
| Q37065591 | Expression and regulation of osteoprotegerin in adipose tissue |
| Q30534404 | Genetic polymorphism of the OPG gene associated with breast cancer |
| Q37806059 | In vitro models for the evaluation of angiogenic potential in bone engineering |
| Q46099636 | Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis |
| Q37146973 | Mechanisms of tooth eruption and orthodontic tooth movement |
| Q82758583 | Osteoclast-like cells in soft tissue leiomyosarcomas |
| Q54391573 | Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. |
| Q51355256 | Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo. |
| Q36088188 | RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas |
| Q64939796 | RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. |
| Q26747442 | RANK-RANKL signalling in cancer |
| Q89967663 | RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies |
| Q36860987 | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. |
| Q38009712 | Skeletal and extraskeletal actions of denosumab. |
| Q35250223 | Skeleton and glucose metabolism: a bone-pancreas loop |
| Q38511945 | Sphingosylphosphorylcholine induces proliferation of human adipose tissue-derived mesenchymal stem cells via activation of JNK. |
| Q40421904 | Targeting non-canonical nuclear factor-κB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis |
| Q98771227 | Targeting the RANKL/RANK/OPG Axis for Cancer Therapy |
| Q64274656 | The Role of Osteoprotegerin and Its Ligands in Vascular Function |
| Q55285084 | The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox |
| Q26851513 | The placental pursuit for an adequate oxidant balance between the mother and the fetus |
| Q38020747 | The role of vascular endothelial growth factor in ossification |
| Q37409192 | Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma |
| Q50071959 | Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic Retinopathy |
| Q36949564 | VEGF: an essential mediator of both angiogenesis and endochondral ossification |
Search more.